Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 6, 2022

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions

Breast CancerHER2-positive Breast Cancer

Interventions

DRUG

Neratinib

Neratinib administered as 40mg tablets

Trial Locations (1)

RECRUITING

University Health Network: Princess Margaret Cancer Centre, Toronto

All Listed Sponsors

lead

University Health Network, Toronto

OTHER